Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 and TFOX in First-line HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07400315Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07400315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400315.